View Older Stories View More Recent Stories

Oct 4, 2021 08:17AM RedHill Biopharma (RDHL) Further Analysis of Phase 2/3 Data Shows 62% Reduction in Mortality with Oral Opaganib in Moderately Severe COVID-19 Patients
Oct 4, 2021 08:15AM RedHill Biopharma (RDHL) Reports Further Analysis of Phase 2/3 Data Including a 62% Reduction in Mortality with Oral Opaganib in Moderately Severe COVID-19 Patients
Oct 4, 2021 08:15AM RedHill Biopharma Reports Further Analysis of Phase 2/3 Data Including a 62% Reduction in Mortality with Oral Opaganib in Moderately Severe COVID-19 Patients
Oct 4, 2021 08:00AM RedHill Biopharma Reports Further Analysis of Phase 2/3 Data Including a 62% Reduction in Mortality with Oral Opaganib in Moderately Severe COVID-19 Patients
Sep 23, 2021 07:00AM RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with Aurobindo
Sep 13, 2021 07:06AM RedHill Biopharma (RDHL) Announces South Africa's Approval of RHB-107 Phase 2/3 COVID-19 Study
Sep 13, 2021 07:02AM RHB-107 P2/3 COVID-19 Study South Africa Approval
Sep 13, 2021 07:00AM RedHill Biopharma Accelerates Ongoing U.S. Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients with South African Approval
Sep 7, 2021 07:10AM RedHill Biopharma (RDHL) Announces Opaganib Demonstrates Significant Decrease of Kidney Fibrosis
Sep 7, 2021 07:02AM RedHill Biopharma's Opaganib Demonstrates Significant Decrease of Kidney Fibrosis
Sep 7, 2021 07:00AM RedHill Biopharma's Opaganib Demonstrates Significant Decrease of Kidney Fibrosis
Sep 7, 2021 06:02AM RedHill Biopharma Ltd Announces New Movantik Analyses at PAINWeek
Sep 7, 2021 06:00AM RedHill Biopharma Presents Three New Analyses of Movantik Data at PAINWeek 2021
Sep 2, 2021 10:35AM RedHill to Present at HCW & Cantor Conferences
Sep 2, 2021 10:00AM RedHill Biopharma to Present at H.C. Wainwright Annual Global Investment and Cantor Global Healthcare Conferences
Aug 26, 2021 07:30AM RedHill Reports Second Quarter 2021 Results
Aug 26, 2021 07:00AM RedHill Biopharma Reports Second Quarter 2021 Financial Results and Operational Highlights
Aug 26, 2021 06:30AM RedHill Biopharma Ltd Announces RedHill's Opaganib Strong Delta Variant Inhibition
Aug 26, 2021 06:00AM RedHill Biopharma (RDHL) Study Shows opaganib's Strong Inhibition of COVID-19 Delta Variant
Aug 26, 2021 06:00AM RedHill Biopharma's Opaganib Demonstrates Strong Inhibition of COVID-19 Delta Variant
Aug 23, 2021 07:08AM RedHill Biopharma (RDHL) Announces Two New U.S. Patents
Aug 23, 2021 07:05AM RedHill Announces Two New U.S. Patents
Aug 23, 2021 07:00AM RedHill Biopharma Announces Two New U.S. Patents Covering Opaganib for Ebola Virus and RHB-104 for Crohn's
Aug 19, 2021 07:00AM RedHill Biopharma to Host Second Quarter 2021 Financial Results and Operational Highlights Webcast on August 26, 2021
Jul 22, 2021 09:45AM RedHill Settles Movantik(R) Apotex Patent Litigation
Jul 22, 2021 09:19AM RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with Apotex
Jul 20, 2021 07:00AM RedHill Biopharma Significantly Extends Unrestricted Commercial Coverage for Talicia® with OptumRx
Jul 19, 2021 10:15AM RedHill Biopharma Ltd Announces RedHill Biopharma Announces Last Patient Out
Jul 19, 2021 07:00AM RedHill Biopharma Announces Last Patient Out for Phase 2/3 COVID-19 Study of Oral Opaganib
Jul 13, 2021 11:03AM RedHill Biopharma (RDHL) Announces Movantik Added as Unrestricted Preferred Brand To A Major National Commercial Formulary Serving over 30 Million Americans
Jul 13, 2021 11:00AM RedHill Biopharma's Movantik® Added as Unrestricted Preferred Brand To A Major National Commercial Formulary Serving over 30 Million Americans
Jun 28, 2021 07:05AM Redhill Biopharma's (REDIF) Opaganib Inhibits COVID-19 Variants in Preclinical Study
Jun 28, 2021 07:00AM RedHill Biopharma's Opaganib Inhibits COVID-19 Variants in Preclinical Study
Jun 21, 2021 07:14AM RedHill Biopharma (RDHL) Announces Presentation of Positive Oral Opaganib Phase 2 Data in COVID-19
Jun 21, 2021 07:00AM RedHill Biopharma Announces Presentation of Positive Oral Opaganib Phase 2 Data in COVID-19
Jun 9, 2021 07:00AM RedHill Biopharma to Present at the BIO Digital International Convention
Jun 7, 2021 07:05AM RedHill Biopharma (RDHL) Reports Complete Enrollment of Oral Opaganib Phase 2/3 COVID-19 Study
Jun 7, 2021 07:00AM RedHill Biopharma Completes Enrollment of Oral Opaganib Phase 2/3 COVID-19 Study
May 27, 2021 07:00AM RedHill Biopharma Reports First Quarter 2021 Financial Results and Operational Highlights
May 26, 2021 07:05AM RedHill Biopharma (RDHL) Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19
May 26, 2021 07:00AM RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19
May 24, 2021 07:00AM RedHill Biopharma Presents Analyses of Movantik Onset of Action and Symptom Improvement at DDW 2021
May 21, 2021 12:15PM RedHill Biopharma Presents a New Travelers' Diarrhea Clinical Severity Classification Tool and its Use in Aemcolo Efficacy Analysis at DDW 2021
May 20, 2021 07:00AM RedHill Biopharma to Host First Quarter 2021 Financial Results and Operational Highlights Webcast on May 27, 2021
Apr 9, 2021 07:02AM RedHill Biopharma's (RDHL) Phase 2/3 COVID-19 Study of Opaganib Passes Fourth DSMB Review with Unanimous Recommendation to Continue
Apr 9, 2021 07:00AM RedHill Biopharma's Phase 2/3 COVID-19 Study of Opaganib Passes Fourth DSMB Review with Unanimous Recommendation to Continue
Mar 25, 2021 09:16AM RedHill Biopharma (RDHL) Announces Settlement of Movantik Patent Litigation with MSN Pharmaceuticals
Mar 25, 2021 09:15AM RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with MSN Pharmaceuticals
Mar 22, 2021 07:05AM RedHill Biopharma (RDHL) Announces Compassionate Use Treatment with Opaganib of first COVID-19 Patients in Switzerland
Mar 22, 2021 07:00AM RedHill Biopharma Announces Compassionate Use Treatment with Opaganib of first COVID-19 Patients in Switzerland
View More Recent Stories View Older Stories